Cell Cycle Proteins and Cancer Therapy
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Biomacromolecules: Proteins".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 2383
Special Issue Editor
Interests: immunotherapy; cancer; checkpoint inhibitors; resistance to cancer; tumor dormancy; melanoma; leukemia; microscale thermophoresis; cytometry; drug screening; in vitro cell culture; in vivo models
Special Issue Information
Dear Colleagues,
During the cell cycle of eukaryotic cells, many proteins are involved in regulation and maintenance. These proteins include kinases and cyclins that regulate movement between the different phases of the cell cycle (interphase, mitosis and cytokinesis), leading to replication and cell division.
Many human cancers exhibit the aberrant activity of various cell cycle proteins (such as cyclin-dependent kinases (CDKs), checkpoint kinases, Aurora kinases and polo-like kinases (PLKs)) and result in the uncontrolled proliferation of tumour cells, tumour dormancy, or recurrence. After decades of research aimed at understanding the functions of cell cycle proteins and their relevance in cancer, cell cycle regulators are now considered interesting targets for cancer treatment.
This Special Issue will focus on recent discoveries regarding the cell cycle proteins and their role in cancer therapy. We invite colleagues to submit their latest research or reviews covering the diagnostic and therapeutic aspects of cell cycle proteins in the broad field of oncology. Topics may include new insights into the mechanisms and pathways involved in cell cycle regulation/control under physiological and pathophysiological conditions, as well as new insights into the regulation of cell cycle mediators/transducers in cancer cells in both in vitro and in vivo models. In addition, papers describing novel inhibitors that target cell cycle transducers in basic and/or clinical settings are welcome.
Dr. Xavier Thuru
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancers
- cyclin-dependent kinases (CDKs)
- checkpoint kinases
- cyclin-dependent kinase inhibitors
- tumor dormancy
